|
NUDT17 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62447832963153E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
4.972300E-04 |
| Normal-vs-Stage3 |
2.97428748297079E-13 |
| Normal-vs-Stage4 |
5.44250000622526E-09 |
| Stage1-vs-Stage2 |
6.768600E-01 |
| Stage1-vs-Stage3 |
2.276000E-01 |
| Stage1-vs-Stage4 |
3.579000E-01 |
| Stage2-vs-Stage3 |
2.587000E-01 |
| Stage2-vs-Stage4 |
3.527400E-01 |
| Stage3-vs-Stage4 |
9.320400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
1.564990E-04 |
| Normal-vs-Asian |
1.12179999733897E-08 |
| Caucasian-vs-AfricanAmerican |
2.409000E-01 |
| Caucasian-vs-Asian |
1.722970E-01 |
| AfricanAmerican-vs-Asian |
6.706400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62458935193399E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
3.988200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
8.28849988643299E-10 |
| Normal-vs-Age(81-100Yrs) |
5.476500E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.734400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.374400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.610400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.212200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.439600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.097200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.956700E-03 |
| Classical-VS-Follicular |
8.02750088624293E-11 |
| Classical-VS-Other |
3.455800E-01 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
2.861000E-03 |
| Tall-VS-Other |
9.868800E-01 |
| Tall-VS-Normal |
2.6741999947788E-08 |
| Follicular-VS-Other |
2.365800E-01 |
| Follicular-VS-Normal |
2.169800E-02 |
| Other-VS-Normal |
6.757900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.30926389122033E-14 |
| Normal-vs-N1 |
2.99569999917537E-08 |
| N0-vs-N1 |
6.654000E-01 |
|
|
